Targeting cells causing split tolerance allows fully allogeneic islet survival with minimal conditioning in NOD mixed chimeras

American Journal of Transplantation

Volumn 12, Issue 12, 2012, Pages 3235-3245

  Al Adra, D P ^a   Pawlick, R ^a   Shapiro, A M J ^a   Anderson, C C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Chimerism; nonobese diabetic; split tolerance

Indexed keywords

BUSULFAN; CD40 LIGAND MONOCLONAL ANTIBODY; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CHRONIC GRAFT REJECTION; DIABETES MELLITUS; FEMALE; FLOW CYTOMETRY; IMMUNOLOGICAL TOLERANCE; IRRADIATION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SKIN TRANSPLANTATION; SPLIT TOLERANCE; STREPTOZOCIN DIABETES; T CELL DEPLETION; TISSUE SPECIFICITY; TREATMENT OUTCOME;

ANIMALS; BONE MARROW; DIABETES MELLITUS, TYPE 1; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C3H; MICE, INBRED NOD; RADIATION CHIMERA; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84870502549     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04260.x     Document Type: Article

References (61)

1. Shapiro AM, Lakey JR, Ryan EA, et al,. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
2. Thompson DM, Meloche M, Ao Z, et al,. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 2011; 91: 373-378.
3. Warnock GL, Thompson DM, Meloche RM, et al,. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008; 86: 1762-1766.
4. Soulillou JP, Giral M,. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001; 72 (Suppl 12): S89-S93.
5. Burke GW, 3rd, Vendrame F, Pileggi A, Ciancio G, Reijonen H, Pugliese A,. Recurrence of autoimmunity following pancreas transplantation. Curr Diab Rep 2011; 11: 413-419.
6. Owen RD,. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400-401.
7. Racine J, Wang M, Zhang C, et al,. Induction of mixed chimerism with MHC-mismatched but not matched bone marrow transplants results in thymic deletion of host-type autoreactive T-cells in NOD mice. Diabetes 2011; 60: 555-564.
8. Manilay JO, Pearson DA, Sergio JJ, Swenson KG, Sykes M,. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 1998; 66: 96-102.
9. Tomita Y, Khan A, Sykes M,. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153: 1087-1098.
10. Chan WF, Perez-Diez A, Razavy H, Anderson CC,. The ability of natural tolerance to be applied to allogeneic tissue: Determinants and limits. Biol Direct 2007; 2: 10. doi:10.1186/1745-6150-2-10
11. Kurtz J, Ito H, Wekerle T, Shaffer J, Sykes M,. Mechanisms involved in the establishment of tolerance through costimulatory blockade and BMT: Lack of requirement for CD40L-mediated signaling for tolerance or deletion of donor-reactive CD4+ cells. Am J Transplant 2001; 1: 339-349.
12. Kurtz J, Shaffer J, Lie A, Anosova N, Benichou G, Sykes M,. Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: Evidence for anergy and deletion but not regulatory cells. Blood 2004; 103: 4336-4343.
13. Wekerle T, Kurtz J, Sayegh M, et al,. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001; 166: 2311-2316.
14. Chan WF, Razavy H, Luo B, Shapiro AM, Anderson CC,. Development of either split tolerance or robust tolerance along with humoral tolerance to donor and third-party alloantigens in nonmyeloablative mixed chimeras. J Immunol 2008; 180: 5177-5186.
15. Chan WF, Razavy H, Anderson CC,. Differential susceptibility of allogeneic targets to indirect CD4 immunity generates split tolerance. J Immunol 2008; 181: 4603-4612.
16. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH,. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med 1985; 162: 231-244.
17. Pasquet L, Joffre O, Santolaria T, van Meerwijk JP,. Hematopoietic chimerism and transplantation tolerance: A role for regulatory T cells. Frontiers in Immunology 2011; 2. doi: 10.3389/fimmu.2011.00080
18. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB,. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709-716.
19. Kawai T, Poncelet A, Sachs DH, et al,. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999; 68: 1767-1775.
20. Kawai T, Cosimi AB, Colvin RB, et al,. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256-262.
21. Kawai T, Cosimi AB, Spitzer TR, et al,. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353-361.
22. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al,. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480-484.
23. Koretz SH, Gottlieb MS, Strober S, et al,. Organ transplantation in mongrel dogs using total lymphoid irradiation (TLI). Transplant Proc 1981; 13 (1 Pt 1): 443-445.
24. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al,. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91: 672-676.
25. Sharabi Y, Abraham VS, Sykes M, Sachs DH,. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: Requirement for chimerism to maintain tolerance. Bone Marrow Transplant 1992; 9: 191-197.
26. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y,. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980; 29: 1-13.
27. Pearson T, Markees TG, Serreze DV, et al,. Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J Immunol 2003; 171: 185-195.
28. Pearson T, Markees TG, Wicker LS, et al,. NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes 2003; 52: 321-326.
29. Al-Adra DP, Chan WF, Anderson CC,. Nonobese diabetic natural killer cells: A barrier to allogeneic chimerism that can be reduced by rapamycin. Transplantation 2011; 92: 977-984.
30. Nikolic B, Onoe T, Takeuchi Y, et al,. Distinct requirements for achievement of allotolerance versus reversal of autoimmunity via nonmyeloablative mixed chimerism induction in NOD mice. Transplantation 2010; 89: 23-32.
31. Nanji SA, Hancock WW, Luo B, et al,. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes 2006; 55: 27-33.
32. Beilhack GF, Landa RR, Masek MA, Shizuru JA,. Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants. Diabetes 2005; 54: 1770-1779.
33. Serreze DV, Chapman HD, Varnum DS, et al,. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: Analysis of a new 'speed congenic' stock of NOD.Igmu(null) mice. J Exp Med 1996; 184: 2049-2053.
34. Kitamura D, Roes J, Kuhn R, Rajewsky K,. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991; 350: 423-426.
35. Ildstad ST, Sachs DH,. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-170.
36. Leventhal J, Abecassis M, Miller J, et al,. Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation. Sci Transl Med 2012; 4: 124ra28.
37. Daikeler T, Hugle T, Farge D, et al,. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant 2009; 44: 27-33.
38. Al-Adra DP, Anderson CC,. Mixed chimerism and split tolerance: Mechanisms and clinical correlations. Chimerism 2011; 2: 89-101.
39. Kishimoto H, Sprent J,. A defect in central tolerance in NOD mice. Nat Immunol 2001; 2: 1025-1031.
40. Zucchelli S, Holler P, Yamagata T, Roy M, Benoist C, Mathis D,. Defective central tolerance induction in NOD mice: Genomics and genetics. Immunity 2005; 22: 385-396.
41. Liston A, Lesage S, Gray DH, et al,. Generalized resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity 2004; 21: 817-830.
42. Mingueneau M, Jiang W, Feuerer M, Mathis D, Benoist C,. Thymic negative selection is functional in NOD mice. J Exp Med 2012; 209: 623-637.
43. Thomas-Vaslin V, Damotte D, Coltey M, Le Douarin NM, Coutinho A, Salaun J,. Abnormal T cell selection on nod thymic epithelium is sufficient to induce autoimmune manifestations in C57BL/6 athymic nude mice. Proc Natl Acad Sci U S A 1997; 94: 4598-4603.
44. Hamilton-Williams EE, Martinez X, Clark J, et al,. Expression of diabetes-associated genes by dendritic cells and CD4 T cells drives the loss of tolerance in nonobese diabetic mice. J Immunol 2009; 183: 1533-1541.
45. Gordon EJ, Wicker LS, Peterson LB, et al,. Autoimmune diabetes and resistance to xenograft transplantation tolerance in NOD mice. Diabetes 2005; 54: 107-115.
46. Wekerle T, Sayegh MH, Hill J, et al,. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187: 2037-2044.
47. Luo B, Chan WF, Shapiro AM, Anderson CC,. Non-myeloablative mixed chimerism approaches and tolerance, a split decision. Eur J Immunol 2007; 37: 1233-1242.
48. Bogunovic M, Ginhoux F, Wagers A, et al,. Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men. J Exp Med 2006; 27: 203: 2627-2638.
49. Markees TG, Serreze DV, Phillips NE, et al,. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes 1999; 48: 967-974.
50. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB,. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114. doi:10.1038/72162
51. Sidiropoulos PI, Boumpas DT,. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13: 391-397.
52. Badell IR, Thompson PW, Turner AP, et al,. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant 2012; 12: 126-135.
53. Page A, Srinivasan S, Singh K, et al,. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant 2012; 12: 115-125.
54. Mehrabi A, Fonouni H, Kashfi A, et al,. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006; 20 (Suppl 17): 30-43.
55. Mangus RS, Fridell JA, Vianna RM, Kwo PY, Chen J, Tector AJ,. Immunosuppression induction with rabbit antithymocyte globulin (rATG) +/- rituximab in 1000 liver transplants with long-term follow-up. Liver Transpl 2012; 18: 786-795.
56. Sobecks RM, Rybicki L, Yurch M, et al,. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS. Bone Marrow Transplant 2011; 47: 633-638.
57. Strahm B, Nollke P, Zecca M, et al,. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: Results of the EWOG-MDS 98 study. Leukemia 2011; 25: 455-462.
58. Nikolic B, Takeuchi Y, Leykin I, Fudaba Y, Smith RN, Sykes M,. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes 2004; 53: 376-583.
59. Guo Z, Wu T, Sozen H, et al,. A substantial level of donor hematopoietic chimerism is required to protect donor-specific islet grafts in diabetic NOD mice. Transplantation 2003; 75: 909-915.
60. Li H, Kaufman CL, Boggs SS, Johnson PC, Patrene KD, Ildstad ST,. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. Journal of Immunology 1996; 156: 380-388.
61. Liang Y, Huang T, Zhang C, et al,. Donor CD8 +T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb. Blood 2005; 105: 2180-2188.